US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
US4908056A
(en)
|
1986-04-25 |
1990-03-13 |
E. I. Du Pont De Nemours And Company |
Heterocyclic acyl sulfonamides
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
EP0352575A3
(de)
|
1988-07-28 |
1991-08-21 |
Bayer Ag |
Substituierte anellierte Pyrrole
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
ATE297465T1
(de)
|
1991-11-25 |
2005-06-15 |
Enzon Inc |
Verfahren zur herstellung von multivalenten antigenbindenden proteinen
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
IT1269176B
(it)
|
1994-01-11 |
1997-03-21 |
Isagro Srl |
Eterobicicli ad attivita' fungicida
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
WO1997008320A1
(en)
|
1995-08-18 |
1997-03-06 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
EP1047761A1
(en)
|
1997-10-14 |
2000-11-02 |
The Procter & Gamble Company |
Hard surface cleaning compositions comprising mid-chain branched surfactants
|
US6982265B1
(en)
|
1999-05-21 |
2006-01-03 |
Bristol Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
MXPA02002938A
(es)
|
1999-09-17 |
2004-12-06 |
Abbott Gmbh & Co Kg |
Inhibidores de cinasa como agentes agentes terapeuticos.
|
TR200103147T1
(tr)
|
1999-12-27 |
2002-06-21 |
Japan Tobacco Inc. |
Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
|
US6770666B2
(en)
|
1999-12-27 |
2004-08-03 |
Japan Tobacco Inc. |
Fused-ring compounds and use thereof as drugs
|
CZ303572B6
(cs)
|
2000-06-28 |
2012-12-12 |
Smithkline Beecham P. L. C. |
Jemne rozmelnený prostredek a zpusob jeho prípravy
|
ES2312568T3
(es)
|
2001-04-06 |
2009-03-01 |
Wyeth |
Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo.
|
AR035543A1
(es)
|
2001-06-26 |
2004-06-16 |
Japan Tobacco Inc |
Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
|
WO2004035580A1
(en)
|
2002-10-21 |
2004-04-29 |
Aprea Ab |
Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
|
EP1576138B1
(en)
|
2002-11-15 |
2017-02-01 |
Idenix Pharmaceuticals LLC. |
2'-methyl nucleosides in combination with interferon and flaviviridae mutation
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
JP2006520385A
(ja)
|
2003-03-13 |
2006-09-07 |
シンタ ファーマスーティカルズ コーポレイション |
縮合ピロール化合物
|
WO2004082638A2
(en)
|
2003-03-17 |
2004-09-30 |
Syrrx, Inc. |
Histone deacetylase inhibitors
|
AU2004253868B2
(en)
|
2003-06-13 |
2011-06-16 |
Biogen Ma Inc. |
Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
|
FR2857966A1
(fr)
|
2003-07-24 |
2005-01-28 |
Aventis Pharma Sa |
Produits aryl-heteroaromatiques, compositions les contenant et utilisation
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
WO2005025515A2
(en)
|
2003-09-12 |
2005-03-24 |
California Institute Of Technology |
Proteasome pathway inhibitors and related methods
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
TW200613306A
(en)
*
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US20070015771A1
(en)
|
2004-07-29 |
2007-01-18 |
Threshold Pharmaceuticals, Inc. |
Lonidamine analogs
|
US20070043057A1
(en)
|
2005-02-09 |
2007-02-22 |
Threshold Pharmaceuticals, Inc. |
Lonidamine analogs
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
KR20070085433A
(ko)
|
2004-11-24 |
2007-08-27 |
노파르티스 아게 |
Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물
|
WO2006124874A2
(en)
|
2005-05-12 |
2006-11-23 |
Kalypsys, Inc. |
Inhibitors of b-raf kinase
|
US8431695B2
(en)
|
2005-11-02 |
2013-04-30 |
Bayer Intellectual Property Gmbh |
Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
|
EP2385053B1
(en)
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
US7514435B2
(en)
|
2005-11-18 |
2009-04-07 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
CN101466710B
(zh)
*
|
2005-12-02 |
2013-05-29 |
拜尔健康护理有限责任公司 |
用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
|
PE20070855A1
(es)
*
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
EP1957078B1
(en)
|
2005-12-02 |
2013-08-28 |
Bayer HealthCare, LLC |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
TWI468162B
(zh)
|
2005-12-13 |
2015-01-11 |
英塞特公司 |
作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶
|
WO2007070872A1
(en)
|
2005-12-15 |
2007-06-21 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and their uses
|
ES2545907T3
(es)
|
2005-12-29 |
2015-09-16 |
Abbvie Inc. |
Inhibidores de proteína quinasa
|
MX2008013110A
(es)
|
2006-04-12 |
2009-03-06 |
Vertex Pharma |
4-5-dihidro-[1,2,4]triazolo[4,3-f]pteridinas como inhibidores de la proteina-cinasa plk1 para el tratamiento de trastornos proliferativos.
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
EP2016077A2
(en)
|
2006-04-25 |
2009-01-21 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
KR20090031544A
(ko)
|
2006-06-29 |
2009-03-26 |
쉐링 코포레이션 |
치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제
|
WO2008012635A2
(en)
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
US8097630B2
(en)
|
2006-10-10 |
2012-01-17 |
Rigel Pharmaceuticals, Inc. |
Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
|
ES2689444T3
(es)
*
|
2006-11-22 |
2018-11-14 |
Incyte Holdings Corporation |
Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
|
WO2008073282A2
(en)
|
2006-12-07 |
2008-06-19 |
Schering Corporation |
Ph sensitive matrix formulation
|
NZ577638A
(en)
|
2006-12-14 |
2012-03-30 |
Vertex Pharma |
Tricyclic fused compounds useful as protein kinase inhibitors
|
EP2074115B1
(en)
|
2006-12-29 |
2018-03-07 |
Rigel Pharmaceuticals, Inc. |
N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
|
CA2710043C
(en)
|
2006-12-29 |
2016-02-09 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
DK2078010T3
(da)
|
2006-12-29 |
2014-04-28 |
Rigel Pharmaceuticals Inc |
Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere
|
MX2009007333A
(es)
|
2007-01-12 |
2009-08-31 |
Biocryst Pharm Inc |
Analogos de nucleosidos antivirales.
|
US8168415B2
(en)
|
2007-02-07 |
2012-05-01 |
The Regents Of The University Of Colorado |
Axl fusion proteins as Axl tyrosine kinase inhibitors
|
US8124759B2
(en)
|
2007-05-09 |
2012-02-28 |
Abbott Laboratories |
Inhibitors of protein kinases
|
DK2155758T3
(da)
|
2007-05-10 |
2012-11-05 |
Biocryst Pharm Inc |
Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
|
EP2173338A1
(en)
|
2007-07-06 |
2010-04-14 |
OSI Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
WO2009008992A2
(en)
|
2007-07-06 |
2009-01-15 |
Osi Pharmaceuticals Inc. |
Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
|
CA2695753A1
(en)
|
2007-08-15 |
2009-02-19 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinases inhibitors
|
WO2009042543A1
(en)
|
2007-09-25 |
2009-04-02 |
Bayer Healthcare Llc |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
AU2008315746A1
(en)
|
2007-10-25 |
2009-04-30 |
Astrazeneca Ab |
Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
|
ES2424259T3
(es)
|
2007-10-26 |
2013-09-30 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con arilo policíclico y heteroarilo policíclico, útiles como agentes inhibidores del Axl
|
DE102007051762A1
(de)
|
2007-10-30 |
2009-05-07 |
Bayer Healthcare Ag |
Substituierte Pyrrolotriazine und ihre Verwendung
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
KR20110017845A
(ko)
|
2008-03-19 |
2011-02-22 |
오에스아이 파마슈티컬스, 인코포레이티드 |
Mtor 억제자 염 형태
|
RU2010146474A
(ru)
|
2008-04-16 |
2012-05-27 |
Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) |
Производные хинолина в качестве ингибиторов axl киназ
|
WO2009132135A1
(en)
|
2008-04-23 |
2009-10-29 |
Gilead Sciences, Inc. |
1' -substituted carba-nucleoside analogs for antiviral treatment
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
KR20110018376A
(ko)
|
2008-06-23 |
2011-02-23 |
스미또모 가가꾸 가부시키가이샤 |
조성물 및 상기 조성물을 이용하여 이루어지는 발광 소자
|
NZ590266A
(en)
|
2008-06-23 |
2012-08-31 |
Vertex Pharma |
Protein kinase inhibitors based on dihydro-5h-pyrimido[4,5-b]diazepin or dihydropteridin
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
WO2010005876A2
(en)
|
2008-07-09 |
2010-01-14 |
Rigel Pharmaceuticals, Inc. |
Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
US8431594B2
(en)
|
2008-07-09 |
2013-04-30 |
Rigel Pharmaceuticals, Inc. |
Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
|
WO2010014755A1
(en)
|
2008-07-29 |
2010-02-04 |
The Regents Of The University Of Colorado |
Methods and compounds for enhancing anti-cancer therapy
|
WO2010025073A1
(en)
|
2008-08-28 |
2010-03-04 |
Takeda Pharmaceutical Company Limited |
Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
|
WO2010048123A2
(en)
|
2008-10-20 |
2010-04-29 |
Eckhardt S Gail |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
WO2010071885A1
(en)
|
2008-12-19 |
2010-06-24 |
Cephalon, Inc. |
Pyrrolotriazines as alk and jak2 inhibitors
|
US20100204265A1
(en)
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
CA2748943A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
WO2010104307A2
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
EA025520B1
(ru)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
|
JP5677425B2
(ja)
|
2009-06-29 |
2015-02-25 |
インサイト・コーポレイションIncyte Corporation |
Pi3k阻害剤としてのピリミジノン
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
WO2011028685A1
(en)
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
NZ599402A
(en)
|
2009-09-21 |
2014-02-28 |
Gilead Sciences Inc |
2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
|
DK2480559T3
(da)
|
2009-09-21 |
2013-08-05 |
Gilead Sciences Inc |
Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
|
SG179207A1
(en)
|
2009-09-25 |
2012-04-27 |
Vertex Pharma |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
HUE043536T2
(hu)
|
2009-10-06 |
2019-08-28 |
Millennium Pharm Inc |
PDK1 inhibitorként alkalmazható heterociklusos vegyületek
|
EP2311809A1
(en)
|
2009-10-16 |
2011-04-20 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinolinyloxyphenylsulfonamides
|
US8604217B2
(en)
|
2009-11-12 |
2013-12-10 |
Selvita S.A. |
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
|
US8680108B2
(en)
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
EP2526102B1
(en)
|
2010-01-22 |
2017-03-08 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Inhibitors of PI3 kinase
|
MX347851B
(es)
|
2010-03-10 |
2017-05-16 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
WO2011123493A1
(en)
*
|
2010-03-31 |
2011-10-06 |
Bristol-Myers Squibb Company |
Substituted pyrrolotriazines as protein kinase inhibitors
|
CA2761074A1
(en)
|
2010-05-05 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
|
US20130131057A1
(en)
|
2010-05-13 |
2013-05-23 |
Centro Nacional De Investigaciones Oncologicas (Cnio |
New bicyclic compounds as pi3-k and mtor inhibitors
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
GB2480814A
(en)
|
2010-06-01 |
2011-12-07 |
Summit Corp Plc |
Compounds for the treatment of clostridium difficile-associated disease
|
BR112013001267A2
(pt)
|
2010-07-19 |
2016-05-17 |
Gilead Sciences Inc |
métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
|
CR20170278A
(es)
|
2010-07-22 |
2017-09-29 |
Gilead Sciences Inc |
Métodos y compuestos para tratar infecciones virales por paramyxoviridae
|
EP2423208A1
(en)
*
|
2010-08-28 |
2012-02-29 |
Lead Discovery Center GmbH |
Pharmaceutically active compounds as Axl inhibitors
|
US20120077814A1
(en)
|
2010-09-10 |
2012-03-29 |
Zhong Wang |
Sulfonamide, sulfamate, and sulfamothioate derivatives
|
TW201305185A
(zh)
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
用於抗病毒治療之2’-氟取代之碳-核苷類似物
|
JP5906191B2
(ja)
|
2010-09-29 |
2016-04-20 |
キッセイ薬品工業株式会社 |
(アザ)インドリジン誘導体及びその医薬用途
|
US9181234B2
(en)
|
2010-10-08 |
2015-11-10 |
Biota Europe Ltd. |
Antibacterial compounds
|
US20120115848A1
(en)
|
2010-10-08 |
2012-05-10 |
Elan Pharmaceuticals, Inc. |
Inhibitors of Polo-Like Kinase
|
ITRM20100537A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
EP2655374B1
(en)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
CA2820709C
(en)
|
2011-02-28 |
2016-02-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted quinoline compounds and methods of use
|
KR20160035613A
(ko)
|
2011-03-23 |
2016-03-31 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
WO2012135800A1
(en)
|
2011-04-01 |
2012-10-04 |
University Of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
JP6047149B2
(ja)
|
2011-05-04 |
2016-12-21 |
インテリカイン, エルエルシー |
併用の医薬組成物およびその使用
|
WO2012154608A1
(en)
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
HUE033019T2
(en)
|
2011-05-17 |
2017-11-28 |
Principia Biopharma Inc |
Tyrosine kinase inhibitors
|
HUE048834T2
(hu)
|
2011-05-17 |
2020-08-28 |
Univ California |
Kináz inhibitorok
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
CA2839767A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
KR20140036269A
(ko)
|
2011-07-01 |
2014-03-25 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
KR102507287B1
(ko)
|
2011-09-02 |
2023-03-07 |
인사이트 홀딩스 코포레이션 |
Pi3k 억제제로서 헤테로시클릴아민
|
WO2013040286A2
(en)
|
2011-09-18 |
2013-03-21 |
Euro-Celtique S.A. |
Pharmaceutical compositions
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
CA2850617A1
(en)
|
2011-10-03 |
2013-04-11 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
CA2854926A1
(en)
|
2011-11-08 |
2013-05-16 |
Intellikine, Llc |
Treatment regimens using multiple pharmaceutical agents
|
HUE033032T2
(hu)
|
2011-11-14 |
2017-11-28 |
Ignyta Inc |
Uracil-származékok mint AXL és c-MET kináz inhibitorok
|
WO2013078440A2
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
US8993756B2
(en)
|
2011-12-06 |
2015-03-31 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
UY34484A
(es)
|
2011-12-15 |
2013-07-31 |
Bayer Ip Gmbh |
Benzotienilo-pirrolotriazinas disustituidas y sus usos
|
JP6047582B2
(ja)
|
2011-12-15 |
2016-12-21 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用
|
PT2810937T
(pt)
|
2012-01-31 |
2017-03-03 |
Daiichi Sankyo Co Ltd |
Derivado de piridona
|
JP5985658B2
(ja)
|
2012-01-31 |
2016-09-06 |
ナンジン アルゲン ファルマ カンパニー リミテッドNanjing Allgen Pharma Co. Ltd. |
ブルトンチロシンキナーゼ阻害薬としての環状分子
|
CN104136439B
(zh)
|
2012-02-23 |
2017-01-18 |
拜耳知识产权有限责任公司 |
取代的苯并噻吩基‑吡咯并三嗪及其用途
|
WO2013151975A1
(en)
|
2012-04-02 |
2013-10-10 |
Northeastern University |
Compositions and methods for the inhibition of methyltransferases
|
CN103373996A
(zh)
|
2012-04-20 |
2013-10-30 |
山东亨利医药科技有限责任公司 |
作为crth2受体拮抗剂的二并环衍生物
|
WO2013162061A1
(ja)
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
EP2861599B1
(en)
|
2012-06-18 |
2019-12-18 |
Principia Biopharma Inc. |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment of cancer and autoimmune diseases
|
JP6236439B2
(ja)
|
2012-06-19 |
2017-11-22 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
ヘテロアリール化合物及びその使用方法
|
CN104395298A
(zh)
|
2012-06-22 |
2015-03-04 |
住友化学株式会社 |
稠合杂环化合物
|
US9572811B2
(en)
|
2012-08-03 |
2017-02-21 |
Principia Biopharma Inc. |
Treatment of dry eye
|
WO2014035140A2
(en)
|
2012-08-30 |
2014-03-06 |
Kainos Medicine, Inc. |
Compounds and compositions for modulating histone methyltransferase activity
|
US10227357B2
(en)
|
2012-09-06 |
2019-03-12 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2014042433A2
(en)
|
2012-09-14 |
2014-03-20 |
Kainos Medicine, Inc. |
Compounds and compositions for modulating adenosine a3 receptor activity
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ire1の調節
|
WO2014059902A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
WO2014059901A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
MX2015005428A
(es)
|
2012-11-01 |
2015-07-21 |
Incyte Corp |
Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
|
EP3251674A3
(en)
|
2012-11-16 |
2018-02-21 |
BioCryst Pharmaceuticals, Inc. |
Antiviral azasugar-containing nucleosides
|
WO2014079545A1
(en)
|
2012-11-20 |
2014-05-30 |
Ktb Tumorforschungsgesellschaft Mbh |
Thioether derivatives as protein kinase inhibitors
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
ES2684776T3
(es)
|
2013-01-18 |
2018-10-04 |
Bristol-Myers Squibb Company |
Ftalazinonas e isoquinolinonas como inhibidores de ROCK
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
WO2014130856A2
(en)
|
2013-02-21 |
2014-08-28 |
Wayne Rothbaum |
Treatment of skeletal-related disorders
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
WO2014164729A1
(en)
|
2013-03-12 |
2014-10-09 |
Arqule, Inc. |
Substituted tricyclic pyrazolo-pyrimidine compounds
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
EP3057970A1
(en)
|
2013-10-18 |
2016-08-24 |
Medivation Technologies, Inc. |
Heterocyclic compounds and methods of use
|
WO2015066371A1
(en)
|
2013-10-31 |
2015-05-07 |
Forum Pharmaceuticals, Inc. |
SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
|
WO2015068767A1
(ja)
|
2013-11-08 |
2015-05-14 |
小野薬品工業株式会社 |
ピロロピリミジン誘導体
|
JP6162904B2
(ja)
*
|
2014-02-03 |
2017-07-12 |
カディラ ヘルスケア リミティド |
新規複素環式化合物
|
CN106170488B
(zh)
|
2014-02-12 |
2020-09-18 |
弗门尼舍公司 |
用于取代的1-苄基-3-(1-(异噁唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2,4-二酮的合成的改进方法
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
WO2016183071A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Hetero-tricyclic compounds and their use for the treatment of cancer
|
WO2017027717A1
(en)
*
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Bicyclic fused pyrimidine compounds as tam inhibitors
|
WO2017035366A1
(en)
|
2015-08-26 |
2017-03-02 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as tam inhibitors
|
US20180296561A1
(en)
|
2015-10-07 |
2018-10-18 |
The University Of North Carolina At Chapel Hill |
The Methods For Treatment Of Tumors
|
US11787809B2
(en)
|
2015-10-13 |
2023-10-17 |
Nihon Nohyaku Co., Ltd. |
Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
|
US9920033B2
(en)
|
2015-11-14 |
2018-03-20 |
Calitor Sciences, Llc |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
WO2017083789A1
(en)
|
2015-11-14 |
2017-05-18 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
KR102558066B1
(ko)
|
2016-03-28 |
2023-07-25 |
인사이트 코포레이션 |
Tam 억제제로서 피롤로트리아진 화합물
|
MX2018012901A
(es)
|
2016-04-22 |
2019-06-06 |
Incyte Corp |
Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
|
AR108875A1
(es)
|
2016-06-24 |
2018-10-03 |
Incyte Corp |
COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
|
JP7197463B2
(ja)
|
2016-07-15 |
2022-12-27 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Smn2の調節のための化合物及び方法
|
JOP20170153A1
(ar)
|
2016-07-15 |
2019-01-30 |
Lilly Co Eli |
نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
|
KR20200088308A
(ko)
|
2017-09-27 |
2020-07-22 |
인사이트 코포레이션 |
Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
|
MA53010A
(fr)
|
2018-06-29 |
2021-05-05 |
Incyte Corp |
Formulations d'un inhibiteur de axl/mer
|
JP2023516441A
(ja)
|
2020-03-06 |
2023-04-19 |
インサイト・コーポレイション |
Axl/mer阻害剤及びpd-1/pd-l1阻害剤を含む併用療法
|